Interpace Biosciences Q3 revenue rises on higher test volume, pricing
IDXG•Interpace Biosciences reported Q3 revenue of $10.37 million, up 18% year over year, as thyroid test volume rose 7% and average revenue per test increased 11%. Adjusted EBITDA rose to $2.1 million, while the company posted a net loss of $1.61 million.
1. Quarterly results
Q3 revenue increased 18% year over year to $10.37 million, driven by a 7% rise in thyroid test volume and an 11% increase in average revenue per test. Adjusted EBITDA rose to $2.1 million, with a 20% margin, and gross margin expanded to 69%. The company reported a net loss of $1.61 million, impacted by non-recurring expenses.
2. Outlook and operations
Interpace expects continued margin expansion supported by operating leverage and efficiency initiatives. It does not expect its pancreatic cancer program to contribute revenue in 2026 or 2027. The company said laboratory efficiency gains and investments in automation and AI-enabled productivity contributed to improved turnaround times and operating leverage.




